This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Yuan, E. Articles by Tycko, B. Search for Related Content PubMed PubMed Citation Articles by Yuan, E. Articles by Tycko, B.

---

Cancer Genes and Genomics

Genomic Profiling Maps Loss of Heterozygosity and Defines the Timing and Stage Dependence of Epigenetic and Genetic Events in Wilms' Tumors

¹ Institute for Cancer Genetics; ² Department of Pediatrics, Division of Pediatric Oncology; ³ Department of Surgery, Division of Pediatric Surgery; and ⁴ Department of Pathology, Columbia University Medical Center, New York, New York

Requests for reprints: Benjamin Tycko, Division of Pathology, Columbia University Medical Center, 630 West 168th Street, New York, NY 10032. Phone: 212-305-1149; Fax: 212-305-5498. E-mail: bt12{at}columbia.edu

To understand genetic and epigenetic pathways in Wilms' tumors, we carried out a genome scan for loss of heterozygosity (LOH) using Affymetrix 10K single nucleotide polymorphism (SNP) chips and supplemented the data with karyotype information. To score loss of imprinting (LOI) of the IGF2 gene, we assessed DNA methylation of the H19 5' differentially methylated region (DMR). Few chromosomal regions other than band 11p13 (WT1) were lost in Wilms' tumors from Denys-Drash and Wilms' tumor-aniridia syndromes, whereas sporadic Wilms' tumors showed LOH of several regions, most frequently 11p15 but also 1p, 4q, 7p, 11q, 14q, 16q, and 17p. LOI was common in the sporadic Wilms' tumors but absent in the syndromic cases. The SNP chips identified novel centers of LOH in the sporadic tumors, including a 2.4-Mb minimal region on chromosome 4q24-q25. Losses of chromosomes 1p, 14q, 16q, and 17p were more common in tumors presenting at an advanced stage; 11p15 LOH was seen at all stages, whereas LOI was associated with early-stage presentation. Wilms' tumors with LOI often completely lacked LOH in the genome-wide analysis, and in some tumors with concomitant 16q LOH and LOI, the loss of chromosome 16q was mosaic, whereas the H19 DMR methylation was complete. These findings confirm molecular differences between sporadic and syndromic Wilms' tumors, define regions of recurrent LOH, and indicate that gain of methylation at the H19 DMR is an early event in Wilms' tumorigenesis that is independent of chromosomal losses. The data further suggest a biological difference between sporadic Wilms' tumors with and without LOI.

This article has been cited by other articles:

				H. T. Bjornsson, L. J. Brown, M. D. Fallin, M. A. Rongione, M. Bibikova, E. Wickham, J.-B. Fan, and A. P. Feinberg Epigenetic Specificity of Loss of Imprinting of the IGF2 Gene in Wilms Tumors J Natl Cancer Inst, August 15, 2007; 99(16): 1270 - 1273. [Abstract] [Full Text] [PDF]

				M. N. Rivera, W. J. Kim, J. Wells, D. R. Driscoll, B. W. Brannigan, M. Han, J. C. Kim, A. P. Feinberg, W. L. Gerald, S. O. Vargas, et al. An X Chromosome Gene, WTX, Is Commonly Inactivated in Wilms Tumor Science, February 2, 2007; 315(5812): 642 - 645. [Abstract] [Full Text] [PDF]

				A. L. Hancock, K. W. Brown, K. Moorwood, H. Moon, C. Holmgren, S. H. Mardikar, A. R. Dallosso, E. Klenova, D. Loukinov, R. Ohlsson, et al. A CTCF-binding silencer regulates the imprinted genes AWT1 and WT1-AS and exhibits sequential epigenetic defects during Wilms' tumourigenesis Hum. Mol. Genet., February 1, 2007; 16(3): 343 - 354. [Abstract] [Full Text] [PDF]

				B. Dekel, S. Metsuyanim, K. M. Schmidt-Ott, E. Fridman, J. Jacob-Hirsch, A. Simon, J. Pinthus, Y. Mor, J. Barasch, N. Amariglio, et al. Multiple Imprinted and Stemness Genes Provide a Link between Normal and Tumor Progenitor Cells of the Developing Human Kidney. Cancer Res., June 15, 2006; 66(12): 6040 - 6049. [Abstract] [Full Text] [PDF]

				E. Yuan, F. Haghighi, S. White, R. Costa, J. McMinn, K. Chun, M. Minden, and B. Tycko A single nucleotide polymorphism chip-based method for combined genetic and epigenetic profiling: validation in decitabine therapy and tumor/normal comparisons. Cancer Res., April 1, 2006; 66(7): 3443 - 3451. [Abstract] [Full Text] [PDF]